Patents by Inventor Benjamin Wang
Benjamin Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200354724Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: July 27, 2020Publication date: November 12, 2020Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 10688132Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: GrantFiled: June 19, 2019Date of Patent: June 23, 2020Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Publication number: 20200188020Abstract: Systems, devices, and methods to treat a urinary bladder are disclosed. An expandable member is introduced and expanded in the urinary bladder to appose one or more elongate conductors on the outer surface of the expandable member against the inner wall of the urinary bladder. The one or more elongate conductors are used to create a predetermined pattern of electrically isolated tissue regions having reduced electrical propagation such that electrical propagation through the urinary bladder as a whole is reduced. A mucus layer may be removed from the inner bladder wall prior to the ablation. Ablation may be regulated by impedance measurement with the one or more elongate conductors. The urinary bladder may be filled with a fluid to facilitate the impedance measurement.Type: ApplicationFiled: February 25, 2020Publication date: June 18, 2020Inventors: Omry BEN-EZRA, Itzhak AVNERI, David STASKIN, Roger A. STERN, Jerome JACKSON, Benjamin WANG
-
Patent number: 10675305Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: GrantFiled: June 19, 2019Date of Patent: June 9, 2020Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Patent number: 10669549Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: GrantFiled: January 10, 2020Date of Patent: June 2, 2020Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20200131520Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: January 10, 2020Publication date: April 30, 2020Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 10610294Abstract: Systems, devices, and methods to treat a urinary bladder are disclosed. An expandable member is introduced and expanded in the urinary bladder to appose one or more elongate conductors on the outer surface of the expandable member against the inner wall of the urinary bladder. The one or more elongate conductors are used to create a predetermined pattern of electrically isolated tissue regions having reduced electrical propagation such that electrical propagation through the urinary bladder as a whole is reduced. A mucus layer may be removed from the inner bladder wall prior to the ablation. Ablation may be regulated by impedance measurement with the one or more elongate conductors. The urinary bladder may be filled with a fluid to facilitate the impedance measurement.Type: GrantFiled: June 10, 2016Date of Patent: April 7, 2020Assignee: NewUro, B.V.Inventors: Omry Ben-Ezra, Itzhak Avneri, David Staskin, Roger A. Stern, Jerome Jackson, Benjamin Wang
-
Publication number: 20200054799Abstract: A suction device for use with a medical device may include a suction device body and an extension. The suction device body may include a first lumen positioned therein and including a plurality of holes. The extension may include a second lumen positioned therein and may be coupled to the suction device body and configured to facilitate connection of the suction device body to a suction line. The second lumen may be in communication with/open to the first lumen and the suction line may be adapted for connection to a pump configured to apply a negative pressure to the first and second lumens. The suction device may evacuate fluids and/or solids from a patient in an area proximate to the suction device.Type: ApplicationFiled: October 12, 2017Publication date: February 20, 2020Inventor: Benjamin Wang
-
Publication number: 20200032273Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: October 16, 2019Publication date: January 30, 2020Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 10508152Abstract: The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) in eukaryotic cells. The present invention also relates to split CARs (Side-CARs) in eukaryotic cells. More specifically, the present invention relates to DEs, RNA Control Devices, and/or side-CARs combined with Chimeric Antigen Receptors to make small molecule actuatable CAR polypeptides. The present invention also relates to DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs for use in the treatment of disease.Type: GrantFiled: September 18, 2017Date of Patent: December 17, 2019Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20190365810Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: ApplicationFiled: June 19, 2019Publication date: December 5, 2019Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Publication number: 20190350977Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: ApplicationFiled: June 19, 2019Publication date: November 21, 2019Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Patent number: 10472637Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: GrantFiled: June 12, 2019Date of Patent: November 12, 2019Assignee: Chimera Bioengingeering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20190309310Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: June 12, 2019Publication date: October 10, 2019Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20190247434Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: ApplicationFiled: February 11, 2019Publication date: August 15, 2019Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Patent number: 10323249Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: GrantFiled: October 3, 2018Date of Patent: June 18, 2019Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 10323248Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: GrantFiled: August 31, 2017Date of Patent: June 18, 2019Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20190178870Abstract: The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.Type: ApplicationFiled: February 14, 2019Publication date: June 13, 2019Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20190104933Abstract: The present disclosure describes devices and methods for treating disorders in a hollow body organ by ablating the tissue therein. At least one set of bipolar electrodes is deployed in the hollow body organ to contact the inner wall of the organ. In the deployed position, each positive electrode is positioned in a location substantially opposite each negative electrode. The tissue contact areas of the positive and negative electrodes are substantially the same and the electrodes are separated from one another by a distance of at least 10 times the width of each of the electrodes. The electrodes thereby produce lesions that are substantially identical to one another and also similar to those produced with monopolar electrodes. The electrodes are used to produce an ablation pattern that can electrically isolate regions of the hollow body organ, thereby treating the disorder(s).Type: ApplicationFiled: December 5, 2018Publication date: April 11, 2019Inventors: Roger A. STERN, Jerome JACKSON, Benjamin WANG, Omry BEN-EZRA, Itzhak AVNERI, Lior AVNERI
-
Patent number: 10222369Abstract: The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.Type: GrantFiled: May 16, 2017Date of Patent: March 5, 2019Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner